Drug Type Proteolysis-targeting chimeras (PROTAC) |
Synonyms |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization- |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC40H39ClFN9O7 |
InChIKeyCYRZHTYQRKEAID-UHFFFAOYSA-N |
CAS Registry2600732-50-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR-mutated non-small Cell Lung Cancer | Preclinical | CN | 01 Jun 2021 | |
EGFR-mutated non-small Cell Lung Cancer | Preclinical | CN | 01 Jun 2021 |